News
Sun Pharmaceutical Industries Ltd. closed 14.47% short of its 52-week high of 1,960.20 rupees, which the company achieved on September 30th.
Sun Pharmaceutical Industries Ltd. closed 14.40% short of its 52-week high of 1,960.20 rupees, which the company reached on September 30th.
June 13 (Reuters) - Sun Pharmaceutical (SUN.NS), opens new tab, India's largest drugmaker by revenue, on Friday named Kirti Ganorkar as managing director, effective September 1. The company's ...
Sun Pharma’s share price continues to be under pressure and is down 2% in trade today. Nomura maintained its ‘Neutral’ rating on the stock and retained a target price of Rs 1,970 per share.
Sun Pharmaceutical Industries Ltd., India's largest drugmaker, announced a significant leadership transition, appointing Kirti Ganorkar as Managing Director, effective September 1, 2025.
Poor Manufacturing: Dr Reddy’s, Sun Pharma, Aurobindo Recall Products In US - IndiaWest Journal News
Similarly, Aurobindo Pharma is recalling 13,605 bottles of Clorazepate Dipotassium Tablets (3.75 mg and 7.5 mg) from the US market. Clorazepate Dipotassium Tablets are used to treat anxiety.
The Sensex jumped 747 points to 82,188.99, while the Nifty 50 breached the 25,000-mark, closing at 25,003.05. | Photo Credit: iStockphoto ...
Sun Pharma successfully removed an injunction on the launch of its Leqselvi for alopecia areata, a common form of hair loss, in the US. Sun Pharma has agreed to acquire Checkpoint Therapeutics ...
India's Sun Pharmaceutical has signed an agreement to acquire US biotech Concert Pharmaceuticals and its lead drug deuroxilitinib, in phase 3 testing for alopecia areata, a leading cause of hair loss.
With the stock's current price at Rs 1,651.20, Sun Pharmaceutical Industries experienced a downturn in today's session, influenced by bearish investor sentiment.
Local News FOX45: Maryland agrees to join Purdue Pharma settlement All eligible states, U.S. territories sign on to $7.4B settlement By Lexi Harpster UPDATED: June 16, 2025 at 5:38 PM EDT ...
Purdue Pharma’s $7B opioid settlement could advance after states back it The deal calls for members of the Sackler family who own the company to give up ownership and to contribute up to $7 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results